Introduction to Whole Body Pet Ct

In order to identify an occult malignancy, a whole-body PET/CT or PET/MRI scan is recommended.

Methods: Images from conventional scan by 68Ga-PSMA whole-body PET/CT or PET/MR followed by delayed pelvic PET/MR were retrospectively analyzed.

Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis.

Methods: SMGGN patients who were diagnosed and treated in the Department of Thoracic Surgery in our hospital from October 2017 to May 2020 and underwent whole-body PET/CT and/or contrast-enhanced brain MRI examinations were enrolled in this study.

Whole-body PET/CT with a field of view from the mandible to the carina was obtained.

3, followed by two whole-body PET/CT scans acquired from 60 and 90 min post-injection.

Visual Intestinal 18F-FDG uptake is variable in whole-body PET/CT.

Twenty-nine paediatric oncology patients (12F/17M, 3–18 years old (median age 13y), weight 45±20 kg, BMI 19±4 kg/m2), who underwent routine whole-body PET/CT examinations on a Siemens Biograph mCT TrueV system with TOF capability (555ps) were included in this study.

Methods Eight 89 Zr-immunoPET whole-body PET/CT scans from three 89 Zr-immunoPET clinical trials were selected for analysis.

Relevant parameters, such as patient ID, patient mass and height, injected activity, and uptake time, were investigated in the case of adult 18 F-FDG whole-body PET/CT and 99m Tc-MDP gamma camera bone scans on a daily basis.

Conventional whole-body PET/CT has limited specificity and sensitivity in the qualitative diagnosis of small lesions and micro-lymph nodes but total-body PET/CT, in which the entire body is scanned in a single shot using a 194-cm axial PET scanner, has opened new avenues for lesion detection [2].

SCI consisted of contrast-enhanced (CE) computed tomography (CT) of the chest/abdomen/pelvis, abdominal/pelvic CE-MR, and/or CE whole-body PET/CT with diagnostic quality (i.

9 years) who underwent whole-body PET/CT were included.

Four sets of images were created by editing four-phase dynamic whole-body PET/CT images acquired at a bed speed of 6 and 14 mm/s in the trunk and lower extremities, respectively.

These findings underline the potential predictive role of quantitative, dynamic, interim PET/CT—performed in combination with conventional, static, whole-body PET/CT—in metastatic melanoma patients under PD-1 blockade.

Local control within the irradiated field and the state of metastatic spread were assessed by periodic whole-body PET/CT and/or MRI imaging.

Methods and materials: 91 patients underwent whole-body PET/CT with either FAPI-04 (N = 25) or FAPI-46 (N = 66).

We perform patient-independent fivefold cross-validation on 3D volumes collected from whole-body PET/CT scans of patients with lymphomas.

The addition of neck PET/MR scan after whole-body PET/CT may provide more favorable diagnostic information.

Following the dynamic acquisition, a whole-body PET/CT was acquired.

Whole-body PET/CT imaging of male and female mice were carried out 2 h after [18F]FDG ip administration under 3% isoflurane anesthesia.

A whole-body PET/CT examination entails approximately 14 mSv, whereas a labeled leukocyte scan entails approximately 7–8 mSv.

The technical validation phase of the equipment consisted of a pilot, prospective and observational study whose objective was to obtain the first images (40 patients), analyze them and make adjustments in the acquisition, reconstruction and correction parameters, comparing the image quality of the CareMiBrain equipment with that of the whole-body PET/CT.

Whole-body PET/CT imaging was performed 50-70 minutes after each injection.

Methods First, 199 patients who received whole-body PET/CT examinations were retrospectively retrieved.

BMB/BMS and whole-body PET/CT results were used as reference standards against which we calculated the diagnostic value of pelvic MRI for BMinv in DLBCL patients.

This research aimed to assess the biokinetics and radiation dosimetry of [68Ga]Ga-iPSMA-BN in four healthy volunteers based on biodistribution data obtained from whole-body PET/CT studies, as well as to visualize the [68Ga]Ga-iPSMA-BN tumor uptake in a patient with PCa.

All whole-body PET/CT reports from 1 January 2010 to 31 December 2013 were retrospectively reviewed and further analyzed if visually increased thyroidal FDG uptake was reported.

At the same time, the whole-body PET/CT may detect additional foci of infection with impact on subsequent treatment strategy.

Further imaging examinations, such as CT or whole-body PET/CT, confirmed that the primary lesions of all the 5 patients were from the lung.

5 MBq/kg): two regional head and neck and upper mediastinum studies at 5 min (first phase) and 120 min (third phase) and a whole-body PET/CT (from the skull vertex to mid-thighs) at 60 min (second phase).

MATERIALS AND METHODS Based on a random sampling method, the results of whole-body PET/CT scan with 18F-FDG glucose in 134 patients with various non-urological disorders were analyzed.

All patient underwent primary whole-body PET/CT examinations at the time of initial staging and intermediate follow-up PET/CT scan after 2-cycle of chemotherapy.

The authors report a case of unresectable primary lymph nodal gastrinoma with liver metastases in a 14-year-old adolescent boy with proven histopathology detected on Ga-DOTANOC whole-body PET/CT scan followed by preoperative multiple Lu-DOTATATE cycles for cytoreduction.

Localization of multiple organs from whole-body PET/CT image is a prerequisite step of automated PET/CT image analysis.

While whole-body PET/CT in conjunction with an abdominal MRI may serve as a comprehensive approach for baseline staging, follow-up with PET/MRI may be preferred for those with liver-only disease.

Methods: Whole-body dosimetry was performed in 3 healthy male subjects by consecutive whole-body PET/CT scanning, estimation of the normalized cumulated activity, and calculation of the effective dose using OLINDA (v1.

The aim of this study was to determine the extent to which 18F-NaF uptake is correlated with calcification at arterial plaques in cancer patients undergoing whole-body PET/CT imaging.

In the clinical study, 5 healthy volunteers and 8 patients with gynecologic cancer underwent whole-body PET/CT after being injected with 68Ga-DOTA-TMVP1.

Patients and methods Sixty patients undergoing PET/CT using fluorine-18-fluorodeoxyglucose (18F-FDG) had dynamic imaging of the liver for 30 min after injection before undergoing whole-body PET/CT at 60 min after injection.

Dynamic whole-body PET/CT images were acquired for up to 140 min after injection of 250 MBq of [18F]GP1.

Both healthy participants (3 females, 3 males) and patients underwent whole-body PET/CT to determine the biodistribution of [11C]CSar.

The aim of this study was to evaluate the physical performance of the Vereos whole-body PET/CT system according to the National Electrical Manufacturers Association (NEMA) NU2-2012 standard and to compare it with other state-of-the-art PET/CT systems.

We conducted a retrospective study on 55 datasets of whole-body PET/CT scans to evaluate the proposed method.

MethodsBiodistribution and radiation dosimetry studies were performed in three HV (mean age 30 ± 2 years, two women) using whole-body PET/CT.

The aim of this study was to develop an accurate simulation and reconstruction model for the Philips Vereos digital whole-body PET/CT scanner.

Sixty minutes post injection a whole-body PET/CT scan was conducted with an emission time of 3 min per bed position.

We included patients with malignant melanoma who underwent a single injection [18F]FDG dual-imaging protocol that included whole-body PET/CT and subsequent whole-body PET/MRI for staging or restaging purposes in a prospective setting.

Whole-body PET/CT showed no tumor, but a cerebellar, cingulate, and prefrontal hypometabolism (Fig.

4 MBq) followed by serial whole-body PET/CT scans and blood tests to assess biodistribution, pharmacokinetic, and radiation dosimetry at 10 min, 1 h, 2 h, and 4 h after injection.

In our proposed method, high-uptake regions in the breast and axilla were detected using db PET images and whole-body PET/CT images.

Data from eight whole-body PET/CT scans, covering the head and the entire torso, were analyzed, including CT raw data and waveform measurements based on a pressure sensor in a belt around the patient’s chest.

Whole-body PET/CT scan revealed an isolated FDG-avid lesion in the left labia majora region, which on histopathology was found to be metastasis from carcinoma rectum.

In Japan, the combined use of dbPET and whole-body PET/CT is necessary in indications for health insurance.

PURPOSE We have developed a second-generation virtual-pinhole (VP) PET device that can position a flat-panel PET detector around a patient's body using a robotic arm to enhance the contrast recovery coefficient (CRC) and detectability of lesions in any region-of-interest using a whole-body PET/CT scanner.

Chapters 4 to 7 discuss patient preparation, standardized uptake value, quantitative whole-body PET/CT imaging, normal variants and benign findings, and interpretation of FDG PET studies.

In case of negative LDCT and presence of CTC, a contrast enhanced whole-body PET/CT will be performed for extra-pulmonary malignancy screening.

After whole-body PET/CT, a centered gated acquisition of both PET and CT was simultaneously obtained with the SGD and RPM during normal breathing.